Vir Biotechnology (VIR) director sells 22,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Vir Biotechnology, Inc. director Vicki L. Sato reported an open-market sale of 22,000 shares of common stock on May 1, 2026 at a weighted average price of $10.0466 per share.

The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2025. After this transaction, she continues to hold 1,078,391 shares of Vir Biotechnology common stock directly.

Insights

Equity markets analyst

Director’s 22,000-share sale is a small, pre-planned transaction.

Director Vicki L. Sato sold 22,000 Vir Biotechnology common shares in an open-market transaction at a weighted average price of $10.0466 on May 1, 2026. This is a straightforward insider sale reported on Form 4.

The filing states the trades were executed under a Rule 10b5-1 trading plan adopted on March 27, 2025, indicating they were pre-scheduled rather than opportunistic. Following the sale, she still directly owns 1,078,391 shares, so the transaction represents a small portion of her disclosed holdings.

Insider Trade Summary 10b5-1

Net Seller: 22,000 shares ($221,025)

Net Sell 1 txn

Insider SATO VICKI L

Role null

Sold 22,000 shs ($221K)

Type	Security	Shares	Price	Value
Sale	Common Stock	22,000	$10.0466	$221K

Holdings After Transaction: Common Stock — 1,078,391 shares (Direct, null)

Footnotes (1)

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Key Figures

Shares sold: 22,000 shares Average sale price: $10.0466 per share Post-transaction holdings: 1,078,391 shares +1 more

4 metrics

Shares sold 22,000 shares Open-market sale on May 1, 2026

Average sale price $10.0466 per share Weighted average for reported trades

Post-transaction holdings 1,078,391 shares Shares directly owned after sale

Price range $9.94–$10.23 per share Range of individual trade prices

Key Terms

Rule 10b5-1 trading plan, open-market sale, weighted average price

3 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SATO VICKI L

(Last) (First) (Middle)

C/O VIR BIOTECHNOLOGY, INC.

1800 OWENS STREET, SUITE 900

(Street)

SAN FRANCISCO CALIFORNIA 94158

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/01/2026		S(1)		22,000	D	$10.0466(2)	1,078,391	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Remarks:

	/s/ Vanina de Verneuil, Attorney-In-Fact	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Vir Biotechnology (VIR) report for Vicki L. Sato?

Vir Biotechnology director Vicki L. Sato reported selling 22,000 shares of common stock. The sale occurred in the open market on May 1, 2026 at a weighted average price of $10.0466 per share, according to the Form 4 filing.

At what prices did Vicki L. Sato sell Vir Biotechnology (VIR) shares?

The shares were sold at a weighted average price of $10.0466. According to the filing, individual transactions occurred in a price range from $9.94 to $10.23 per share, with the director willing to provide full breakdowns upon request.

Was the Vir Biotechnology (VIR) director’s share sale under a Rule 10b5-1 plan?

Yes. The Form 4 states the sales were effected under a Rule 10b5-1 trading plan adopted by director Vicki L. Sato on March 27, 2025. Such plans pre-schedule trades, reducing the significance of timing as a discretionary signal.

How many Vir Biotechnology (VIR) shares does Vicki L. Sato hold after the sale?

After selling 22,000 shares, Vicki L. Sato directly holds 1,078,391 shares of Vir Biotechnology common stock. This indicates the reported sale represents only a small fraction of her disclosed ownership position in the company.

What type of transaction did Vir Biotechnology (VIR) disclose in this Form 4?

The filing discloses an open-market sale of common stock by director Vicki L. Sato. The transaction is coded as an “S” sale, reflecting 22,000 non-derivative shares sold, with no associated option exercises or derivative security activity reported.